Sign in
WithdrawnPhase 3

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Key facts

Who runs it
AbbVie
Where
Atlanta, Chicago, Cleveland, Jacksonville, Oklahoma City, Roanoke, Silver Spring, and Washington D.C., United StatesSee the 8 sitesAlso in 1 other country, 2 sites
Trial code
Status
Withdrawn
Phase
Phase 3
Started
15 Sept 2025
Ended
19 Jul 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Mesalamine
  • Placebo
Record updated
12 August 2025
Why it stopped
strategic considerations

Who can take part

Age
5 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Documented history of Ulcerative Colitis (UC) who have been successfully maintained in remission for at least 30 days prior to the screening visit and are on a stable dose of mesalamine or 5-aminosalicylic acid equivalent

Who cannot take part

  • Abnormal and clinically significant results according to the investigator or designee, on physical examination, medical history, electrocardiogram (ECG), hematology, clinical chemistry, or urinalysis

Where in United States

Also in 1 other country, 2 sites

  • Treken Primary CareAtlanta, United States
  • Eagle Clinical ResearchChicago, United States
  • UH Cleveland Medical CenterCleveland, United States
  • Angel Kids PediatricsJacksonville, United States
  • Children's Hospital OklahomaOklahoma City, United States
  • Carilion Medical CenterRoanoke, United States
  • Virgo Carter PediatricsSilver Spring, United States
  • Childrens NationalWashington D.C., United States

About the trial

What the trial wants to find out

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by diffuse, continuous inflammation of the colon. This study will assess how safe and effective mesalamine delayed-release capsules are in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed.

Read full original descriptionShow less

Delzicol (Mesalamine) is an approved drug being developed for the treatment of Ulcerative Colitis (UC). Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Around 80 Pediatric participants aged 5 to 17 years with a diagnosis of UC will be enrolled in approximately 45 sites in the United States.

Participants will receive oral mesalamine capsules twice daily for 26 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

The 2 groups in the trial

  • Mesalamine Dose ATreatment being tested

    Participants will receive mesalamine Dose A twice daily for 26 weeks.

    Treatment: Mesalamine

  • Mesalamine Dose BTreatment being tested

    Participants will receive mesalamine Dose B twice daily for 26 weeks.

    Treatment: Mesalamine and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
Record updated
12 August 2025